MedImmune Ventures appoints Ron Laufer
pharmafile | June 18, 2010 | Appointment | Research and Development |Â Â AstraZeneca, MedImmune, appointment, research and developmentÂ
Ron Laufer has joined MedImmune’s venture capital arm as senior managing director.
The company, which is the worldwide biologics unit for AstraZeneca, said Laufer wold strengthen its long-term commitment to supporting scientific innovation through strategic venture capital investments.
“I am delighted to join MedImmune Ventures at this exciting time in biopharmaceutical research,” said Laufer. “I look forward to building on a successful history and supporting promising products and companies as they pursue our shared commitment to improving patient health.”
Laufer has more than 15 years industry experience, during which he co-founded Lilly Ventures, Eli Lilly and Company’s corporate venture capital fund.
He was also a managing director for healthcare-focused investment firm Visium Asset Management.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …






